Immunosuppression for Immune-Related Adverse Events During Checkpoint Inhibition: an Intricate Balance

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but come with severe immune-related adverse events (irAEs). To prevent fatality or chronicity, these irAEs are often promptly treated with high-dose immunosuppressants. Until recently, evidence on the effects of irAE management on ICI efficacy has been sparse. As a result, algorithms for irAE management are mostly expert-opinion based and barely consider poss…

Immune Checkpoint Inhibitors and Survival Disparities by Health ...

Common Autoimmune Drug May Help Reverse Immunotherapy-Induced Diabetes, UCLA Study Finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor-induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs.

Autoimmune Disorder Therapy Drug Reverses Immunotherapy-Related Diabetes in Mouse Model

A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor (ICI)–induced type 1 diabetes mellitus (ICI-T1DM) using an existing class of drugs used to treat autoimmune disorders. The preclinical study, headed by Melissa Lechner, PhD, assistant professor of medicine in the division of endocrinology, diabetes, and metabolism at the…